Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from AN2 Therapeutics, Inc. ( (ANTX) ) is now available.
On January 26, 2026, AN2 Therapeutics’ board appointed Sarah Williams, previously the company’s Corporate Controller, as Vice President, Controller and Principal Accounting Officer, effective February 1, 2026, with an increased annual base salary of $310,000 and eligibility for standard company indemnity, severance and incentive arrangements. As part of a broader cost-savings effort and transition of the Principal Accounting Officer role, the company amended Chief Financial Officer Lucy Day’s employment terms on January 29, 2026, maintaining her positions as CFO and Principal Financial Officer but reducing her annual base salary from $335,400 through March 2026 to $223,600 from April 1, 2026, while adjusting her severance eligibility and preserving the vesting of her outstanding equity awards, signaling tighter financial discipline and a rebalancing of executive compensation.
The most recent analyst rating on (ANTX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on AN2 Therapeutics, Inc. stock, see the ANTX Stock Forecast page.
Spark’s Take on ANTX Stock
According to Spark, TipRanks’ AI Analyst, ANTX is a Neutral.
The score is primarily held back by weak financial performance (no revenue, ongoing losses, and negative free cash flow), partially offset by a low-debt balance sheet and improving burn trends. Technicals are constructive with the stock trading above major moving averages and a positive MACD, but valuation remains constrained by negative earnings and no dividend yield support.
To see Spark’s full report on ANTX stock, click here.
More about AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. operates in the biotechnology and pharmaceutical industry, focusing on the development of novel therapeutics, with a corporate structure that includes dedicated finance and accounting leadership to support its growth and compliance needs.
Average Trading Volume: 89,399
Technical Sentiment Signal: Hold
Current Market Cap: $33.02M
For detailed information about ANTX stock, go to TipRanks’ Stock Analysis page.